Valence 로고
인기
로그인
Loading data for FBIOP — first visit, this takes a few seconds.

관심목록에 추가

Fortress Biotech Inc.

NasdaqCM: FBIOP · 실시간 가격 · USD
18.20
-0.06 (-0.33%)
종가 기준: Aug 19, 2026, 8:00 PM
18.18
-0.14%
애프터마켓: 5:09 PM

Fortress Biotech Inc. (FBIOP) Stock Price, Analysis & Data

-0.33%

데이터 없음

매수호가n/a
시가총액n/a
매출 (ttm)68.47M
순이익 (ttm)103.37M
베타1.21
EPS (ttm)-0.86
P/E (ttm)n/a
선행 P/En/a
P/B (ttm)3.69
P/S (ttm)n/a
Earnings Daten/a
매도호가n/a
거래량11,493
평균 거래량 (20일)21,595
시가18.23
전일 종가18.26
일중 범위18.05 - 18.34
52주 범위6.27 - 21.43
애널리스트n/a
목표주가n/a
배당n/a
배당락일2024년 6월 14일

FBIOP 소개

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical ...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Nov 14, 2017
직원 수 78
상장 거래소 NasdaqCM
티커 FBIOP
웹사이트 https://www.fortressbiotech.com
전체 기업 정보

재무 실적

2025년 Fortress Biotech의 매출은 63.26M로, 전년 57.67M 대비 9.69% 증가했습니다. 순이익은 6.82M로, -114.82% 감소했습니다.

재무제표
news image

5일 전 · Moby

Fortress Biotech, Inc. Q2 2026 Earnings Call Summary

Moby summary of Fortress Biotech, Inc.'s Q2 2026 earnings call

news image

5일 전 · Motley Fool

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Emrosi prescriptions jumped 20% sequentially with payer coverage climbing to 38%.

news image

6일 전 · MarketBeat

Fortress Biotech Q2 Earnings Call Highlights

Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Exe...

news image

1개월 전 · Simply Wall St.

Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes

Journey Medical is back in focus as analysts revisit their price targets in light of fresh information around its role inside Fortress Biotech and the implied value of its shares and cash position. Re...

news image

5개월 전 · TipRanks

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Re...

2 페이지 중 1